Skip to main content

Dr. Van K. Morris II, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2008
Medicare patients seen, 2024
94

Licensed in Texas since 2012, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Medical school: University of Tennessee, Hsc, College of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    TX license P2738 (first issued 2012; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
94
Services billed
238
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes10554
Established patient office or other outpatient visit, 30-39 minutes8040
Established patient office or other outpatient visit, 20-29 minutes3830
New patient office or other outpatient visit, 60-74 minutes3030
Established patient office or other outpatient visit, 10-19 minutes1514

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Prochlorperazine Maleate
Other prescribers in Houston, TX
16
Loperamide (loperamide hcl)
Other prescribers in Houston, TX
14
Ondansetron Hcl
Other prescribers in Houston, TX
14
Lonsurf (trifluridine/tipiracil hcl)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 9 companies reported 34 payments worth $29,846 in total to this clinician.

By company
Incyte Corporation$9,751
BioNTech SE$5,580
GlaxoSmithKline, LLC.$4,353
E.r. Squibb & Sons, L.l.c.$3,162
AbbVie Inc.$2,791
Pfizer Inc.$2,232
Exelixis Inc.$1,825
Immunitybio, Inc.$83.47
By type
Consulting Fee$24,630
Travel and Lodging$2,560
Honoraria$1,650
Food and Beverage$1,006

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 18, 2025Incyte Corporation
Dec 18, 2025
Consulting Fee$7,193
Jun 16, 2025BioNTech SE
Jun 16, 2025
Consulting Fee$4,713
Apr 15, 2025GlaxoSmithKline, LLC.
Apr 15, 2025
Consulting Fee$2,987
Jun 6, 2025AbbVie Inc.
Jun 6, 2025
Consulting Fee$2,658
Jun 13, 2025E.r. Squibb & Sons, L.l.c.
Jun 13, 2025
Consulting Fee$2,250
Jun 17, 2025Pfizer Inc.
Jun 17, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$2,160
May 22, 2025Exelixis Inc.
May 22, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,650
Sep 19, 2025Incyte Corporation
Sep 19, 2025
Consulting Fee$1,370
Oct 20, 2025E.r. Squibb & Sons, L.l.c.
Oct 20, 2025
Consulting Fee$900
Feb 24, 2025GlaxoSmithKline, LLC.
Feb 24, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$545
All 19 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 18, 2025Incyte Corporation
Dec 18, 2025
Consulting Fee$7,193
Nov 14, 2025Incyte Corporation
Nov 14, 2025
Travel and Lodging
travel to Philadelphia, PA
$142
Nov 13, 2025Incyte Corporation
Nov 13, 2025
Travel and Lodging
travel to Philadelphia, PA
$509
Nov 13, 2025Incyte Corporation
Nov 13, 2025
Travel and Lodging
travel to Philadelphia, PA
$266
Nov 13, 2025Incyte Corporation
Nov 13, 2025
Travel and Lodging
travel to Philadelphia, PA
$197
Oct 20, 2025E.r. Squibb & Sons, L.l.c.
Oct 20, 2025
Consulting Fee$900
Sep 19, 2025Incyte Corporation
Sep 19, 2025
Consulting Fee$1,370
Aug 22, 2025GlaxoSmithKline, LLC.
Aug 22, 2025
Consulting Fee$400
Jun 17, 2025Pfizer Inc.
Jun 17, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$2,160
Jun 16, 2025BioNTech SE
Jun 16, 2025
Consulting Fee$4,713
Jun 13, 2025E.r. Squibb & Sons, L.l.c.
Jun 13, 2025
Consulting Fee$2,250
Jun 6, 2025AbbVie Inc.
Jun 6, 2025
Consulting Fee$2,658
May 31, 2025BioNTech SE
May 31, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$182
May 28, 2025BioNTech SE
May 28, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$328
May 28, 2025BioNTech SE
May 28, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
$182
May 22, 2025Exelixis Inc.
May 22, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,650
Apr 15, 2025GlaxoSmithKline, LLC.
Apr 15, 2025
Consulting Fee$2,987
Mar 24, 2025GlaxoSmithKline, LLC.
Mar 24, 2025
Travel and Lodging
travel to Boston, MA · in-kind
$208
Feb 24, 2025GlaxoSmithKline, LLC.
Feb 24, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$545

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $825,020 in research payments for these studies, mostly to the institutions running them.

  • First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
    Merck Sharp & Dohme LLC
  • A phase two, open label,multicenter,master protocol to evaluate the safety and efficacy of novel study interventions and combinations in participants with colorectal cancer cantor
    AstraZeneca UK Limited
  • An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
    Pfizer Inc.
  • Phase Ib trial of encorafenib cetuximab and nivolumab in BRAF mutated metastatic colorectal cancer
    E.r. Squibb & Sons, L.l.c.
  • A phase 2 randomized openlabel study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated braf V600EMUTANT msi hdmmr metastatic colorectal cancer
    Pfizer Inc.
  • BNT-122-01
    BioNTech SE
  • BNT122
    BioNTech SE
  • Phase 1 Study of Oral TP-1454
    Sumitomo Pharma America, Inc. · Completed · NCT04328740
  • An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line tre…
    Novartis Pharmaceuticals Corporation
  • BNT314-02
    BioNTech SE

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 8, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1134396534. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.